The c-MYC oncogene encodes a transcription factor, which is sufficient and necessary for the induction of cellular proliferation. However, the c-MYC protein is a relatively weak transactivator suggesting that it may have other functions. To identify protein interactors which may reveal new functions or represent regulators of c-MYC we systematically identified proteins associated with c-MYC in vivo using a proteomic approach. We combined tandem affinity purification (TAP) with the mass spectral multidimensional protein identification technology (MudPIT). Thereby, 221 c-MYC-associated proteins were identified. Among them were 17 previously known c-MYC-interactors. Selected new c-MYC-associated proteins (DBC-1, FBX29, KU70, MCM7, Mi2-b/CHD4, RNA Pol II, RFC2, RFC3, SV40 Large T Antigen, TCP1a, U5-116kD, ZNF281) were confirmed independently. For association with MCM7, SV40 Large T Antigen and DBC-1 the functionally important MYC-box II region was required, whereas FBX29 and Mi2-b interacted via MYC-box II and the BR-HLH-LZ motif. In addition, regulators of c-MYC activity were identified: ectopic expression of FBX29, an E3 ubiquitin ligase, decreased c-MYC protein levels and inhibited c-MYC transactivation, whereas knock-down of FBX29 elevated the concentration of c-MYC. Furthermore, sucrose gradient analysis demonstrated that c-MYC is present in numerous complexes with varying size and composition, which may accommodate the large number of new c-MYC-associated proteins identified here and mediate the diverse functions of c-MYC. Our results suggest that c-MYC, besides acting as a mitogenic transcription factor, regulates cellular proliferation by direct association with protein complexes involved in multiple synthetic processes required for cell division, as for example DNA-replication/repair and RNA-processing. Furthermore, this first comprehensive description of the c-MYC-associated sub-proteome will facilitate further studies aimed to elucidate the biology of c-MYC.
ABsTRACT
The c-MYC oncogene encodes a transcription factor, which is sufficient and necessary for the induction of cellular proliferation. However, the c-MYC protein is a relatively weak transactivator suggesting that it may have other functions. To identify protein interactors which may reveal new functions or represent regulators of c-MYC we systematically identified proteins associated with c-MYC in vivo using a proteomic approach. We combined tandem affinity purification (TAP) with the mass spectral multidimensional protein identification technology (MudPIT). Thereby, 221 c-MYC-associated proteins were identified. Among them were 17 previously known c-MYC-interactors. Selected new c-MYC-associated proteins (DBC-1, FBX29, KU70, MCM7, Mi2-b/CHD4, RNA Pol II, RFC2, RFC3, SV40 Large T Antigen, TCP1a, U5-116kD, ZNF281) were confirmed independently. For association with MCM7, SV40 Large T Antigen and DBC-1 the functionally important MYC-box II region was required, whereas FBX29 and Mi2-b interacted via MYC-box II and the BR-HLH-LZ motif. In addition, regulators of c-MYC activity were identified: ectopic expression of FBX29, an E3 ubiquitin ligase, decreased c-MYC protein levels and inhibited c-MYC transactivation, whereas knock-down of FBX29 elevated the concentration of c-MYC. Furthermore, sucrose gradient analysis demonstrated that c-MYC is present in numerous complexes with varying size and composition, which may accommodate the large number of new c-MYC-associated proteins identified here and mediate the diverse functions of c-MYC. Our results suggest that c-MYC, besides acting as a mitogenic transcription factor, regulates cellular proliferation by direct association with protein complexes involved in multiple synthetic processes required for cell division, as for example DNA-replication/repair and RNA-processing. Furthermore, this first comprehensive description of the c-MYC-associated sub-proteome will facilitate further studies aimed to elucidate the biology of c-MYC.
INTRoDuCTIoN
The proto-oncogene c-MYC regulates cellular proliferation, growth, competition, replicative potential, differentiation, and apoptosis (reviewed in refs. 1 and 2). Expression of c-MYC is rapidly induced by diverse mitogens, whereas it is downregulated during differentiation. Deregulated expression of c-MYC has been implicated in the genesis of many types of tumors. 3 Activation of c-MYC is sufficient for the induction of cell cycle progression, and the phenotype of conditional c-MYC knockout mice implies that c-MYC function is essential for proliferation in most cell types. 4 The c-MYC protein acts as a transcription factor, which regulates a large number of genes involved in preparing cells for division. [5] [6] [7] However, the effect of c-MYC on the expression of its target genes is relatively weak with maximum inductions in the range of 2-to 3-fold suggesting that the c-MYC protein may perform additional functions, which contribute to its dramatic effects on cellular proliferation and growth. We reasoned that these suspected functions of c-MYC may be deduced from novel c-MYC-associated proteins. In order to identify new c-MYC-interacting proteins, we performed a comprehensive proteomic analysis by combining tandem affinity purification (TAP) 8 with the multidimensional protein identification technology (MudPIT). 9 MudPIT employs multidimensional liquid chromatography to separate the components of proteolyzed protein complexes, which are detected online by tandem mass spectrometry. Together with the advantages of tandem affinity purification, such as minimal background and preservation of native protein complexes, the ability of MudPIT to analyze complex peptide mixtures promised to allow the comprehensive characterization of the c-MYC-associated sub-proteome. Our results significantly extend the number of c-MYC-interacting proteins and suggest additional nontranscriptional functions for c-MYC. Further analysis of the c-MYC-associated proteins identified here will significantly contribute to the resolution of the function of this important oncogene.
MATeRIAL AND MeTHoDs
Cell culture and ectopic gene expression. DLD1 colorectal cancer cells and DLD1-tTA cells expressing a tet-repressor-VP16 fusion 10 were cultivated in McCoy's 5A medium (Invitrogen) supplemented with 10% foetal bovine serum (FBS). Human embryonic kidney (HEK) 293T and Phoenix-Eco cells were kept in high-glucose Dulbecco's modified eagle medium (DMEM; Invitrogen) supplemented with 5% FBS. All media contained 100 U/ml penicillin and 100 mg/ml streptomycin. For generation of stable cell lines, DLD1 and DLD1-tTA cells were subjected to lipofection (Lipofectamine 2000; Invitrogen) with pBI-c-MYC-TAP or pBI-TAP in combination with pTK-Hyg (Clontech). Limiting dilutions were performed in the presence of G418 (500 mg/ml), hygromycin B (250 mg/ml), or puromycin (1 mg/ml), respectively. DLD1-tTA cells were propagated in the presence of doxycycline (500 ng/ml).
Expression constructs. Expression constructs were generated using standard PCR and cloning techniques. Plasmids were verified by sequence analysis. Detailed information will be provided on request.
Cell-based reporter assay. HEK293T cells were transiently transfected with 500 ng pGL2-M4-luc E-box promoter construct containing the firefly luciferase gene, 13 ng of the expression vector for renilla luciferase pRL-CMV (Promega), and 375 ng of respective transactivator constructs. Equal plasmid molarity was achieved by adjusting total plasmid amounts with empty vector. Cells were harvested 24 hours after transfection and activities of firefly and renilla luciferase were measured using the Dual-Luciferase reporter assay system (Promega).
Bimolecular fluorescence complementation (BIFC) assay. HEK293T cells were transiently transfected with expression constructs for pECFP-C1 (Clontech), pMK10tTA, and Flag-Max-YN-pBI-HA -c-MYC-YC and a 10-fold excess of pBI-c-MYC, pBI-c-MYC-TAP, pBI-TAP, or pMAX-HA. The bidirectional Flag-Max-YN-pBI-HA-c-MYC-YC vector was derived from pCMV-HA-MYC-YC and pFlag-CMV2-Max-YN (gift from Tom Kerppola 11 ). HEK293T were cultured at 30˚C after changing the medium and analyzed by fluorescence microscopy 24 hours after transfection.
Tandem affinity purification (TAP). HEK293T cells were transiently transfected 24 hours before the TAP procedure with the vectors pMK10tTA and pBI-c-MYC-TAP or pBI-TAP using calcium phosphate precipitation. In DLD1-tTA cell lines stably transfected with either pBI-c-MYC-TAP or pBI-TAP, expression was induced for 48 hours by doxycycline withdrawal. TAP was performed as described 12 with minor modifications. Briefly, 10 semiconfluent 500 cm 2 -plates (corresponding to 1 x 10 9 cells) were lysed in TAP lysis buffer containing 10 mM Tris/HCl pH 8.0, 250 mM NaCl, 10 mM MgCl 2 , 0.1% Nonidet P-40 or Triton X-100, 1 mM DTT, protease inhibitor cocktail (Complete Mini EDTA-free; Roche), 2 mM sodium-orthovanadate, 2.5 ml/ml phosphatase inhibitors (Cocktail 1; Sigma), and 5 ml/ml DNase I (Roche) for each purification. Pellets were shock-frozen in liquid nitrogen three times and subsequently all supernatants were combined. Binding of about 100 mg of protein lysate to 800 ml IgG-sepharose beads (Amersham Pharmacia Biotech) was performed for 14 hours at 4˚C. Extensive washing with TAP washing buffer and tobacco etch virus (TEV) cleavage buffer was followed by 2.5 hours incubation with 200 U recombinant TEV protease (Invitrogen) at 10˚C. The eluate of the TEV cleavage reaction was diluted in calmodulin binding buffer and applied to 400 ml calmodulin affinity resin (Stratagene). After four hours incubation at 10˚C, the beads were washed repeatedly with calmodulin binding buffer. Finally, calmodulin bound protein complexes were subjected to 40 min nondenaturing elution with TAP elution buffer and precipitated using trichloroacetic acid (TCA).
Multidimensional protein identification technology (MudPIT). Precipitated c-MYC-TAP-and TAP-associated protein preparations were dissolved in digestion buffer, digested with trypsin, and analyzed by LC/LC/MS/MS according to published protocols. 13 Approximately 100 mg of protein were used for a 12-step LC/ LC/MS/MS analysis on a LCQ Classic (ThermoElectron, San Jose, CA). The obtained MS/MS spectra were analyzed with SEQUEST 2.7 using a nonredundant mammalian database (May 2003 release, NCBI). 14 The SEQUEST outputs were then analyzed by DTASelect. 15 The DTASelect filter settings were: XCorr: +1 ions 1.8, +2 ions 2.5, +3 ions 3.8; DCN: 0.08; only half or full tryptic peptides were considered, and all subset proteins were removed (the "-o" option in DTASelect). Proteins with four to five peptides that passed the DTASelect filter were considered real hits. Proteins with one to three peptides that passed the DTASelect filter were manually validated.
Cell lysis, Western blot analysis and antibodies. Total cell lysates were obtained using Triton X-100 lysis buffer (10 mM Tris/HCl pH 8.0, 150 mM NaCl, 1% Triton X-100, 2 mM sodium-orthovanadate, and 1 mM DTT) supplemented with protease inhibitor tablets (Complete Mini, Roche). Polyclonal rabbit anti-MYC (sc-764), rabbit anti-MAX (sc-765), rabbit anti-CDC2 (sc-954), rabbit anti-HA (sc-805), rabbit anti-GFP (sc-8334) antibodies and monoclonal mouse anti-a-Tubulin (sc-8035) and anti-MCM7 (sc-9966) antibodies were from Santa Cruz Biotechnology. Monoclonal mouse anti-DNA-Polymerase d and e (#610972, #611238) and anti-KU70 (#611892) antibodies from BD Biosciences. Goat anti-Protein A antibody (ab6659) from Abcam, mouse anti-HA (MMS-101P) from Covance, rabbit anti-Actin from Sigma. Monoclonal mouse anti-RNA-Polymerase II (8WG16), mouse anti-c-MYC (9E10), and mouse anti-HA (12CA5) antibodies were generous gifts from Dirk Eick. Rabbit anti-RAF1, monoclonal mouse anti-VSV (p5d4) and anti-Large T Antigen (KT3), rabbit anti-U5-116kD, rabbit anti-RFC3, rabbit anti-MCM7, rat anti-TCP1a, and mouse pan-anti-MYC antibodies were kindly provided by Axel Ullrich, Karl H. Scheidtmann, Rheinhard Lührmann, Jerard Hurwitz, Rolf Knippers, Franz U. Hartl, and Naohiko Ikegaki, respectively. Polyclonal anti-DBC-1 antibodies were generated by immunizing rabbits with Ni-NTA (nickel-nitrilotriacetic acid; Qiagen) purified recombinant DBC-1-His fusion protein (amino acids 1-479). Monospecific antibodies were purified from serum by affinity chromatography with Sulfo-Link (Pierce) coupled with recombinant His-tagged DBC-1 (amino acids 1-479). Detection was performed using HRP-conjugated secondary antibodies (Promega), enhanced chemiluminescence reagent (Perkin Elmer), and a 440CF imaging system (Kodak).
Immunodetections. Cells were grown on CELLocate slides (Eppendorf ) or on Lab-Tek II Chamber Slides (Nunc) and fixed with 3.7% paraformaldehyde for 15 min, blocked with 50% FBS and incubated with antibodies diluted in PBS/10% FBS/0.05% Tween 20. Double-staining was performed by subsequent incubation with primary antibodies and detection with goat-anti-mouse-FITC and goat-anti-rabbit-Cy3 (Jackson ImmunoResearch Laboratories)
antibodies.
Yeast two-hybrid assay. Plasmids encoding fusion proteins with either the Gal4 DNA-binding domain (BD) or the Gal4 activation domain (AD) were cotransformed into the reporter strain CG-1945 and plated on synthetic media lacking leucine and tryptophan with 2% glucose as the carbon source. Positive transformants were replica plated onto indicator plates to screen for histidine prototrophy in the presence of 25-50 mM 3-aminotriazole (Sigma) to repress background growth.
Immunoprecipitation. HEK293T cells were harvested 24 hours after calcium phosphate transfection in TNT-buffer (20 mM Tris/ HCl pH 7.5, 200 mM NaCl, 0.5-1% Triton X-100, 1 mM DTT, and protease inhibitor tablets). Protein complexes were bound by specific antibodies for three hours and subsequently collected by incubating with protein G-sepharose (Amersham Biosciences) or protein A-agarose (Sigma) beads for one hour at 4˚C with rotation. After five times washing with TN-buffer (20 mM Tris/HCl pH 7.5, 200 mM NaCl, 0.1% Triton X-100, and 1 mM DTT), proteins were eluted by boiling in 1x Laemmli buffer, separated by SDS-PAGE, and detected by Western blot analysis.
Sucrose gradient sedimentation analysis. Sucrose gradient sedimentation experiments were performed with either tandem affinity-purified c-MYC-TAP-associated protein complexes or HeLa nuclear extract. Tandem affinity purification was carried out with the DLD1-tTA cell line stably transfected with pBI-c-MYC-TAP as described above. The c-MYC-TAP-myc-eluate purified from 1 x 10 9 cells was concentrated to 500 ml using Amicon Ultra 15 (Millipore). HeLa cell nuclear extracts were prepared according to Dignam et al. Briefly, HeLa cells were harvested and washed in PBS (pH 7.4). Cell pellets were resuspended in two pellet volumes of buffer A (10 mM KCl, 10 mM HEPES KOH pH 7.9, 1.5 mM MgCl 2 , 0.5 mM PMSF, 1mM NaF, Roche protease inhibitor cocktail), incubated on ice for 15 min and homogenized by passing through a 27-gauge needle five times. Subsequently, cytoplasm and nuclei were separated by centrifugation of the suspension in a bench top centrifuge at 13000 rpm for 5 min at 4˚C. Nuclei were resuspended in buffer C (420 mM NaCl, 20 mM HEPES-KOH pH 7.9, 1.5 mM MgCl 2 , 0.5 mM PMSF, 0.2 mM EDTA, 5% glycerol, 2 mM Na 3 VO 4 , 1 mM NaF, Roche protease inhibitor cocktail, Sigma phosphotase inhibitor cocktails I), homogenized by passing 10 times through a 27-gauge needle and stirred for 30 min on ice. Nuclear extracts were obtained after centrifugation at 13,000 rpm for 30 min at 4˚C. Nuclear extract (500 ml, ~1-2 mg total protein) or concentrated c-MYC-TAP-eluate (500 ml) was layered on a 5-35% (w/v) linear sucrose gradient containing 150 mM NaCl, 50 mM TrisHCl pH 7.4 and 5 mM MgCl 2 , 2 mM Na 3 VO 4 , Roche protease inhibitor cocktail. After centrifugation at 40,000 rpm for 18 hours in a Beckman SW41 rotor, 0.5 ml fractions were collected and proteins were methanol/ chloroform precipitated. Proteins were separated by SDS-PAGE and analyzed by Western blot analyses. Molecular sizes of the fractions were determined by a gradient in which marker proteins Aldolase (158 kD), Catalase (232 kD) and Thyroglobulin (670 kD) were separated.
RNA interference. For RNA interference the TMP vector, 16 a doxocyclin-repressible system, was used in combination with the tTA-expressing vector pMK10tTA (0.5 mg) in HEK293T cells. The target sequences for the respective microRNAs used were: FBX29: 5'-ACCTTACGAATTGGCAATCAAT-3'; Non-silencing: 5'-ATCTCGCTTGGGCGAGAGTAAG-3'. The effectiveness of the FBX29-specific microRNA was confirmed by downregulation of the protein level of HA-tagged FBX29 48 hours after co-transfection of 293 cells using Western blot analysis (data not shown).
ResuLTs

TAP/MudPIT-mediated identification of c-MYC-associated proteins. The c-MYC open reading frame was fused to the TAP
The c-MYC open reading frame was fused to the TAP tag to generate a c-MYC-TAP fusion protein (Fig. 1A) . Transient transfection of this fusion protein led to activation of an E-box containing reporter plasmid to a similar degree as c-MYC (Fig. 1B) . Furthermore, c-MYC-TAP competed with c-MYC for binding to MAX in a bimolecular fluorescence complementation (BIFC) assay indicating that the TAP-tag moiety does not interfere with c-MYC/ MAX heterodimerization (Supplemental Fig. S1 ). For the BIFC analysis, MAX and c-MYC were fused to the N-and C-terminal halves of yellow fluorescent protein (YFP), respectively. As a consequence, an YFP signal is emitted only when these fusion proteins heterodimerize. 11 In addition, ectopic expression of c-MYC-TAP was sufficient to rescue the slow proliferation phenotype of c-MYCdeficient RAT-1 fibroblasts (Supplemental Fig. 2 ). In summary, these results demonstrated that the c-MYC-TAP fusion represents a functional c-MYC protein. Two human cell lines derived from epithelial cells were used for our analyses as they allowed the identification of c-MYC-interactors also present in carcinomas, which represent the majority of human tumors. For transient expression of c-MYC-TAP, human embryonic kidney cells (HEK293T), which express adenoviral E1A/E1B and SV40 large T Antigen (LTAg), were employed because of their high transfection efficiency of >95% (data not shown). For moderate expression of the bait protein, DLD1 colorectal cancer cell lines with conditional expression of c-MYC-TAP or the TAP tag under the control of a tet-operator, which is repressed in the presence of doxycycline, were generated (Fig. 1C) . As expected, the c-MYC-TAP fusion protein showed exclusively nuclear localization, whereas the isolated TAP protein was present in both nucleus and cytoplasm (Fig. 1C) .
Tandem affinity purifications were performed after induction of expression of c-MYC-TAP and, as a control, of the TAP tag in stable DLD1 cell lines or after transient expression of the respective proteins in HEK293T cells. For each tandem affinity purification 10 9 cells were employed. The presence of copurified proteins in the final eluates was confirmed by SDS-PAGE (Fig. 1D) . After a tryptic digest of the final eluate, peptides were identified by MudPIT analysis. In total, six combined TAP/MudPIT analyses were performed resulting in the identification of 336 proteins. Highly abundant proteins (e.g., keratins and ribosomal proteins), which were also associated with the TAP tag alone, and proteins frequently found in previously reported TAP tag purifications using other bait proteins were considered as background and excluded (summarized in Tables S1 and S2 in the Supplemental Data available online). The remaining set of 221 proteins associated with c-MYC is provided in Table 1 . Proteins were assigned to functional classes and in each class the protein identifications were sorted according to the frequency of their detection in the six combined TAP/MudPIT analyses. The indicated amino acid sequence (%) coverage represents the percentage of the protein covered by matching tryptic peptides and generally decreases with increasing protein size. Therefore, the coverage is comparatively low for proteins larger than 300 kD as p400, TRRAP, and HectH9. The frequency of detection combined with sequence coverage may serve as a rough estimate of the affinity and directness of the association with c-MYC. Seven previously described c-MYC-interactors were identified in at least four of the six MudPIT analyses and showed moderate to high sequence coverage. The order of average sequence coverage among these proteins was MAX > a-Tubulin > TIP49 > TIP48 > PRKDC > TRRAP > HectH9. In some cases known interactors were detected in only one or two out of six purifications (FBXW7, GTF2I, BAF53A, and RAF1). In total, 17 previously described c-MYC-binding proteins were identified by our approach (shaded black in Table 1 ). Furthermore, we noticed that 59 of the 221 (~27%) c-MYC-associated proteins were encoded by genes, which are listed as c-MYC-induced genes, www.myc-cancer-gene.org, indicated in Table 1 ).
Validation of MudPIT identifications. Twelve exemplary mass-spectral protein identifications were confirmed by detection of the respective proteins in the c-MYC-TAP (MT) eluate and absence from the TAP (T) eluate using specific antibodies ( Fig. 2A) . Furthermore, ectopic c-MYC was coprecipitated with endogenous DBC-1, KU70, MCM7, LTAg, and U5-116kD proteins (Fig. 2B ). For two selected proteins (DBC-1 and MCM7), the interaction was verified on the level of endogenous proteins (Fig. 2C ). In addition, nuclear colocalization with endogenous c-MYC protein was confirmed for seven newly identified interactors (Supplemental Fig. S3 ). For DBC-1, a polyclonal antibody was raised against amino acids 1-479 of DBC-1 (data not shown). Analogous to c-MYC, these proteins displayed a strictly nuclear localization with nucleolar exclusion.
To exclude the possibility that c-MYC-associated proteins were generally copurified in the TAP procedure and in coimmunoprecipitations, we analyzed selected interactions using a yeast two-hybrid assay. Thereby, the interactions of c-MYC with DBC-1, MCM7, ZNF281, and FBX29 were confirmed (Fig. 2D) .
MCM7, LTAg and DBC-1 interact with MYC-box II. We mapped the regions of c-MYC necessary for the association with three novel c-MYC-interactors by coimmunoprecipitation using a set of c-MYC deletion mutants (Fig. 3) . The conserved MYC-box II was indispensable for the interaction with MCM7, a protein involved in licensing of DNA replication, which was detected in four c-MYC-TAP purifications (Fig. 3A and Table 1 ). The C-terminal region of MCM7 presumably mediated the binding to c-MYC since deletion of residues 1-432 did not interfere with c-MYC association (data not shown). N-terminal fragments of MCM7 were not analyzed by coimmunoprecipitation as they displayed cytoplasmic localization. MCM7 has been implicated in the transcriptional regulation of its own promoter, which is induced by c-MYC. 17 However, ectopic expression of MCM7 did not influence c-MYC-mediated transcriptional activation in a transient reporter assay (data not shown). Therefore, the interaction with c-MYC is presumably not involved in the autoregulation of MCM7. Association of c-MYC with LTAg, which has structural and functional similarity to MCM7, was also dependent on the presence of the conserved MYC-box II (Fig. 3A) . Numerous other proteins involved in DNA replication and/or licensing were identified, although with a lower frequency (see Table 1 ), suggesting that c-MYC may be directly involved in this process. Among others, MCM2, RFC2, RFC3, RFC5, DNA polymerase e and d were copu- rified with c-MYC.
The association of DBC-1 with c-MYC was also mediated by MYC-box II (Fig. 3A) . Recently, DBC-1 has been implicated in TNFa-induced apoptosis 18 : DBC-1 is cleaved in a caspase-dependent manner and the resulting C-terminal fragments (DBC-1-p120 and DBC-1-p66) are relocalized to the cytoplasm. Ectopic DBC-1-p120 causes mitochondrial clustering and sensitizes cells to apoptosis, whereas no pro-or anti-apoptotic function could be assigned to full-length DBC-1. The biological role of the association of DBC-1 with the conserved MYC-box II, which is essential for all known functions of c-MYC, 3 remains to be determined in the future.
Several components of the repressive NURD chromatin remodeling complex were identified by our analysis: CHD4/Mi-2b, TIP48, TIP49, HDAC1, HDAC2 and TRIM28 (Table 1 ). The interaction with CHD4/Mi-2b was validated and detailed using immunoprecipitation analysis (Fig. 3B) . Interestingly, both the conserved MYC-Box II and the C-terminal BR-HLH-LZ domain of c-MYC were necessary for the interaction with Mi-2b.
FBX29 inhibits c-MYC function. The conserved MYC-box II and the C-terminal BR-HLH-LZ domain of c-MYC were also necessary for the interaction with FBX29 (Fig. 4A) . This finding is reminiscent of the interaction requirements of SKP2, a previously characterized c-MYC interactor involved in the regulation of c-MYC activity by ubiquitination. FBX29 is a component of the SCF7-complex, which harbors E3-ubiquitin ligase activity. 19 When both proteins were coexpressed increasing amounts of FBX29 led to a decrease in the total amount of ectopic c-MYC protein (Fig. 4B) . When FBX29 was down-regulated by RNA interference the amount of c-MYC protein increased (Fig. 4C) . Furthermore, coexpression of FBX29 with c-MYC inhibited the transactivation of an E-box containing reporter gene construct by c-MYC (Fig. 4D) . Presumably, the association of FBX29 with c-MYC inactivates c-MYC by targeting it for proteasomal degradation. Importantly, these results show that the interactors identified here may represent critical regulators and effectors of c-MYC function.
Parallel existence of multiple different c-MYC-containing complexes. The large number of c-MYC-associated proteins detected here raised the question as to whether these proteins exist in one s exist in one exist in one large c-MYC-containing complex or rather in multiple, separate complexes of varying size. To distinguish between these possibilities we performed a sucrose gradient size fractionation after tandem affinity purification of c-MYC-TAP-associated protein complexes in DLD1 cells (Fig. 5A ). c-MYC was detected in fractions 4 to 20 (of 23 fractions in total). Therefore, c-MYC is present in a large number of protein complexes with a broad range of molecular weights. As expected its obligate dimerization partner MAX was detected in the majority of these fractions (3 to 19). Interestingly, RNA polymerase II was mainly present in fractions 13 to 15, whereas the replication associated protein MCM7 was detected in fractions 6-14. The distribution of DBC-1 overlapped largely with the distribution of MCM7, whereas U5-116kD was present in fractions 6-8 as well as fractions 17-19 and therefore presumably forms an additional c-MYC containing complex. In order to investigate whether the endogenous c-MYC forms a similar pattern of complexes, nuclear HeLa cell extract was subjected to sucrose gradient fractionation and the resulting fractions were probed for the presence of c-MYC and associated proteins (Fig. 5B) . Consistent with the distribution of the c-MYC-TAP protein complexes, endogenous c-MYC was found in diverse molecular weight fractions. As after coprecipitation with the c-MYC-TAP protein, the c-MYC-associated proteins were detected in distinct, mostly nonoverlapping fractions. In summary, these data show that c-MYC exists in a highly complex pattern of diverse nuclear complexes which according to their composition fulfill different functions.
Table 1 Functional classification of c-MYC-associated proteins identified by a combination of tandem affinity purification and MudPIT using c-MYC-TAP as bait (continued)
The numbers indicate amino acid sequence coverage (in %) obtained by mass spectrometry for c-MYC-associated proteins isolated either from transiently transfected HEK293T cells (columns I -III) or DLD1-tTA stable cell lines expressing c-MYC-TAP (columns IV -VI). Black background: previously identified interactions; grey: protein interactions confirmed in this study. *, previously described as a c-MYC target gene.
DIsCussIoN
This manuscript represents the first comprehensive characterization of the c-MYC-associated sub-proteome. The identified interactions strongly suggest that the function of c-MYC is not restricted to regulating gene expression by association with RNA polymerase I, II, and III complexes. Instead, c-MYC presumably influences multiple additional processes involved in cellular proliferation by directly interacting with numerous other protein complexes. In the following paragraphs selected new interactors and their regulation of/by c-MYC will be discussed.
c-MYC has been implicated in the regulation of DNA replication. 20 The most convincing evidence comes from observations in Xenopus, where a maternal, cytoplasmic store of c-MYC protein is recruited to the nucleus until mid-blastula transition. 21 As these developmental stages are transcriptionally silent, the c-MYC protein presumably directly affects DNA replication. Here, at least 12 proteins involved in licensing of DNA replication or DNA replication itself were identified. Binding of c-MYC to the C-terminus of MCM7 may prevent the inhibition of MCM7 by pRB or p130. 22 c-MYC may similarly affect LTAg, which resembles the MCM proteins in structure and function as it also forms a hexameric ring, which unwinds DNA during replication. 23 Furthermore, direct recruitment of MCM7 to DNA by c-MYC could target the licensing machinery to specific origins of DNA replication in the vicinity of E-box elements. For invertebrate organisms, a correlation between the timing of DNA replication and transcriptional activity has been demonstrated. 24 It is conceivable that c-MYC, which participates in the activation of early genes, recruits licensing complexes to these genes. In the future it will be important to determine whether c-MYC recruits MCM7 to E-box sequences, which may potentially serve as origins of replication. Interestingly, we found numerous DNA repair proteins associated with c-MYC which may explain how deregulated c-MYC interferes with DNA repair in tumor cells. 25, 26 In nontransformed cells, the interaction between c-MYC and repair proteins may serve to coordinate DNA repair with transcription or DNA replication. KU70/KU80 heterodimers represent the regulatory subunit of DNA-dependent protein kinase (DNA-PKc), which plays an important role during the repair of DNA double-strand breaks and phosphorylates c-MYC. Down-regulation of DNA-PKc decreases the level of c-MYC protein and its transcriptional activity. 27 It is however also conceivable, that deregulated c-MYC influences the activity of the KU70/KU80/DNA-PKc complex.
c-MYC associated with three subunits of the U5 small nuclear ribonucleoprotein (snRNP), which are important for the formation of the tri-snRNP particle consisting of U5 and U4/U6. Besides its function as a bridging protein between U5 and U4/U6 spliceosome components, the U5-102kD protein associates with the androgen receptor and is involved in cotranscriptional splicing processes. 28 U5-116kD is essential for pre-mRNA splicing, 29 and U5-200kD, a DEXH helicase, is necessary for excision of the RNA lariat during pre-mRNA splicing. 30 Via these interactions, c-MYC may promote an increase of processed mRNA molecules required for cell proliferation.
Numerous chaperones and HSP proteins were found in association with c-MYC. These proteins are highly expressed in proliferating and transformed cells. T-complex (CCT) proteins assist in the folding of newly translated Cyclin E to allow binding of CDK2. 31 The correct folding of c-MYC may be supported by TCP1, CCT2, and CCT3 in a similar manner.
The degradation of the c-MYC protein is highly regulated. 32 c-MYC has a half-life of 20 minutes and is degraded by the 26S proteasome. Among other components of the proteasome our TAP/MudPIT analysis also identified the E3-ligase FBXW7 (also known as hCDC4) and SKP1, which represent components of the SCF complex. These proteins target c-MYC for degradation by ubiquitination by binding of MYC-box I. 33, 34 FBX29 may have similar functions in the regulation of c-MYC activity by protein degradation. Our analysis of FBX29 (also known Our analysis of FBX29 (also known as FBXW8) shows that it represents a new, negative regulator of c-MYC function. What activates FBX29-mediated c-MYC degradation and the molecular details of the ubiquitination, which is presumably mediated by the SCF7 complex, are interesting questions, which can now be approached. To our knowledge c-MYC represents the first reported substrate for FBX29. Additional proteins Additional proteins relevant to the regulation of c-MYC degradation identified here may be the E3-ligase proteins UBR2 and UBE3C. The proteins involved in the degradation of c-MYC identified here represent interesting candidates for mutational inactivation in cancer cells as their loss would lead to an increase in c-MYC activity. Indeed, the hCDC4 gene is inactivated by mutation in a considerable fraction of tumors. 35 However, ubiquitination may also increase c-MYC activity. While this manuscript was in preparation, it was reported that the ubiquitin E3-ligase HectH9 positively regulates the transcriptional activity of c-MYC and is essential for tumor cell proliferation. 36 SMARCA5, SMARCA6 and SMARCC1 are components of ATPdependent chromatin remodeling complexes which may mediate activation of target genes by c-MYC. Besides its role in transcriptional activation, c-MYC has been implicated in gene repression. 1, 20 The repressive NURD chromatin remodeling complex, which contains Mi-2b, TIP48, TIP49, HDAC1, and HDAC2, links ATP-dependent chromatin remodeling and histone deacetylation. 37 TRIM28, which was also identified here, recruits the NURD complex. 38 c-MYC, by interaction with TRIM28 and various components of the NURD complex, could potentially prevent or mediate repression by NURD complexes. Interestingly, Mi-2b has a role in the regulation of stem cell fate 39 and may therefore explain how c-MYC affects stem cells.
ZNF281 (also known as ZBP-99) is a 99 kD protein with four Krueppel type zinc fingers and is highly similar to ZBP-89, which has been implicated in the transcriptional regulation of ornithine decarboxylase (ODC), 40 a well known c-MYC target gene. Therefore, the interaction between c-MYC and ZNF281 may be relevant for the regulation of ODC and presumably other c-MYC target genes.
Besides providing insight into the complexity of c-MYC protein interactions the data presented in this study will serve as a resource for the experimental elucidation of c-MYC biology. Other components of the c-MYC/MAX network may be subjected to this approach to complement this analysis. As protein interactions have been recently found to represent feasible therapeutic targets, 41, 42 interference with some of the interactions identified here may be useful to treat tumors associated with c-MYC activation.
Note
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